132 related articles for article (PubMed ID: 29701074)
1. Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Tampellini M; Bironzo P; Di Maio M; Scagliotti GV
Future Oncol; 2018 May; 14(12):1223-1231. PubMed ID: 29701074
[TBL] [Abstract][Full Text] [Related]
2. [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Kuwabara K; Kumamoto K; Ishibashi K; Okada N; Ishiguro T; Ohsawa T; Haga N; Miura I; Ishida H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2224-7. PubMed ID: 22202337
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
[TBL] [Abstract][Full Text] [Related]
5. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
[TBL] [Abstract][Full Text] [Related]
6. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL
Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
10. 2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression.
Nakajima Y; Madhyastha R; Maruyama M
Anticancer Agents Med Chem; 2009 Feb; 9(2):239-45. PubMed ID: 19199868
[TBL] [Abstract][Full Text] [Related]
11. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Yanagisawa Y; Maruta F; Iinuma N; Ishizone S; Koide N; Nakayama J; Miyagawa S
Scand J Gastroenterol; 2007 Apr; 42(4):477-84. PubMed ID: 17454858
[TBL] [Abstract][Full Text] [Related]
12. Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.
Noda E; Maeda K; Inoue T; Nishihara T; Nishiguchi Y; Ohira M; Hirakawa K
Anticancer Res; 2006; 26(6C):4653-8. PubMed ID: 17214322
[TBL] [Abstract][Full Text] [Related]
13. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
14. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Ikeguchi M; Makino M; Kaibara N
Langenbecks Arch Surg; 2002 Oct; 387(5-6):240-5. PubMed ID: 12410361
[TBL] [Abstract][Full Text] [Related]
15. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
17. Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Bai W; Wu Y; Zhang P; Xi Y
Int J Clin Exp Pathol; 2015; 8(10):12333-45. PubMed ID: 26722420
[TBL] [Abstract][Full Text] [Related]
18. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Yasuno M; Mori T; Koike M; Takahashi K; Toi M; Takizawa T; Shimizu S; Yamaguchi T; Matsumoto H
Oncol Rep; 2005 Mar; 13(3):405-12. PubMed ID: 15706408
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
20. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
